肌萎缩性肥胖
肌萎缩
医学
肥胖
癌症
体质指数
不利影响
人口
肌肉团
临床意义
重症监护医学
内科学
物理疗法
环境卫生
作者
G. Gortan Cappellari,Caterina Brasacchio,Daniela Laudisio,Carla Lubrano,Francesca Pivari,Luigi Barrea,Giovanna Muscogiuri,Gaetano Lombardi,Annamaria Colao
出处
期刊:Nutrition
[Elsevier BV]
日期:2022-02-04
卷期号:98: 111624-111624
被引量:24
标识
DOI:10.1016/j.nut.2022.111624
摘要
Growing evidence suggests that changes in muscle mass and function may further contribute to health risk assessment in individuals who are obese. As numbers for both obese and aged population subgroups are increasing worldwide, sarcopenic obesity is emerging as a relevant factor associated with higher risk for adverse events and outcomes in several clinical settings, including cancer. Recent reports showing that prevalence of sarcopenic obesity may involve up to one-third of patients with cancer despite body mass index strongly support the need for its evaluation in oncological clinical practice. In fact, in several cancer types, sarcopenic obesity is associated with poorer outcomes that include metabolic and surgical complications, longer hospitalization, physical disability, and shorter survival. Importantly, sarcopenic obesity may also have an effect on chemotherapy, as it may induce a higher risk for dose-limiting-toxicity. The aim of this review was to present an updated overview on the definition, effects, mechanisms, and clinical relevance of sarcopenia in this setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI